Evaluating the Effectiveness of Escitalopram to Prevent Depression in Head and Neck Cancer Patients Receiving Treatment

• Status: Completed
• Trial end date: 2012-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the effectiveness of escitalopram to prevent depression in head and neck cancer patients receiving treatment.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Nebraska
• Collaborator: National Institute of Mental Health (NIMH)
• Treatments: Citalopram; Dexetimide

Criteria

Inclusion Criteria:

• Newly diagnosed or recurrent epidermoid cancer of the head and neck

• Requires more than minimal therapy for treatment

• Able to read and write in English

• Willing to use an effective form of birth control throughout the study

Exclusion Criteria:

• Meets MINI criteria for major depression, schizophrenia, or bipolar illness or scores 24 or less

• Suicidal or psychotic

• Current allergy or hypersensitivity to citalopram or other SSRIs

• Treated with monoamine oxidase inhibitors 14 days prior to study entry

• Use of antidepressants within 1 week of study entry

• Pregnant or breastfeeding

• History of an adequate cancer operation, radiation, or chemotherapy within 6 months of study entry

• Diagnosed with melanoma or lymphoma cancer of the head and neck

• Currently participating in another research study involving a therapeutic intervention